Pluristem Therapeutics positive results in pre-clinical test of its PLacental eXpanded (PLX) stem cells for the treatment of pulmonary fibrosis. It reduced pulmonary fibrosis (scarring of the lung tissue) and improved lung function in interstitial lung disease (ILD). http://www.globes.co.il/serveen/globes/docview.asp?did=1000770385&fid=1725

Two months after a second bone marrow transplant failed, surgeons at Hadassah hospital gave PLX stem cells from Israel’s Pluristem to a 7-year old Romanian girl. After 10 days, blood levels improved and nine months later she is to be … Continue reading →

Israeli biotech Pluristem announced that its PLacental eXpanded (PLX) cells improve several parameters in acute heart attacks in animals. Cardiac muscle function improved in mice receiving PLX cells, compared with a control group. Over 600,000 people suffered heart attacks in … Continue reading →

Pluristem Thereputics’s PLX-PAD stem cell treatment has had success in combating critical limb ischemia (blockage of the arteries in the limbs), which can lead to gangrene and amputation. http://www.globes.co.il/serveen/globes/docview.asp?did=1000694761&fid=1725

Israeli biotech Pluristem Therapeutics has announced that initial animal studies found that its placental stem cells can treat Acute Radiation Syndrome (ARS). http://www.globes.co.il/serveen/globes/docview.asp?did=1000680388&fid=1725

Israel biotech Pluristem has received orphan drug status from the US Food and Drugs Administration for its stem cell treatment of blood vessels disease. http://www.globes.co.il/serveen/globes/docview.asp?did=1000676759&fid=1725

Haifa-based Pluristem’s unique PLX cells have been selected for development into a product for treating pulmonary hypertension, which (if untreated) can lead to heart failure. http://www.globes.co.il/serveen/globes/docview.asp?did=1000655953&fid=1725